|
1
|
World Cancer Reports 2014. http://publications.iarc.fr/Non-Series-Publications/World-Cancer-Reports/World-Cancer-Report-2014September
27–2016
|
|
2
|
U.S. National Cancer Institute and World
Health Organization, . The Economics of Tobacco and Tobacco
Control. National Cancer Institute Tobacco Control Monograph 21.
NIH Publication No. 16-CA-8029A. U.S. Department of Health and
Human Services, National Institutes of Health, National Cancer
Institute. Bethesda, MD: World Health Organization, Geneva;
2016
|
|
3
|
Yano T, Miura N, Takenaka T, Haro A,
Okazaki H, Ohba T, Kouso H, Kometani T, Shoji F and Maehara Y:
Never-smoking nonsmall cell lung cancer as a separate entity:
Clinicopathologic features and survival. Cancer. 113:1012–1018.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Subramanian J and Govindan R: Lung cancer
in never smokers: A review. J Clin Oncol. 25:561–570. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Pao W and Girard N: New driver mutations
in non-small-cell lung cancer. Lancet Oncol. 12:175–180. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mitsudomi T: Molecular epidemiology of
lung cancer and geographic variations with special reference to
EGFR mutations. Transl Lung Cancer Res. 3:205–211. 2014.PubMed/NCBI
|
|
7
|
Brandt B, Meyer-Staeckling S, Schmidt H,
Agelopoulos K and Buerger H: Mechanisms of egfr gene transcription
modulation: Relationship to cancer risk and therapy response. Clin
Cancer Res. 12:7252–7260. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kohno M, Okamoto T, Suda K, Shimokawa M,
Kitahara H, Shimamatsu S, Konishi H, Yoshida T, Takenoyama M, Yano
T and Maehara Y: Prognostic and therapeutic implications of
aromatase expression in lung adenocarcinomas with EGFR mutations.
Clin Cancer Res. 20:3613–3622. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Garon EB, Pietras RJ, Finn RS, Kamranpour
N, Pitts S, Márquez-Garbán DC, Desai AJ, Dering J, Hosmer W, von
Euw EM, et al: Antiestrogen fulvestrant enhances the
antiproliferative effects of epidermal growth factor receptor
inhibitors in human non-small-cell lung cancer. J Thorac Oncol.
8:270–278. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Niikawa H, Suzuki T, Miki Y, Suzuki S,
Nagasaki S, Akahira J, Honma S, Evans DB, Hayashi S, Kondo T and
Sasano H: Intratumoral estrogens and estrogen receptors in human
non-small cell lung carcinoma. Clin Cancer Res. 14:4417–4426. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shimizu K, Hirami Y, Saisho S, Yukawa T,
Maeda A, Yasuda K and Nakata M: Membrane-bound estrogen receptor-α
expression and epidermal growth factor receptor mutation are
associated with a poor prognosis in lung adenocarcinoma patients.
World J Surg Oncol. 10:1412012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Raso MG, Behrens C, Herynk MH, Liu S,
Prudkin L, Ozburn NC, Woods DM, Tang X, Mehran RJ, Moran C, et al:
Immunohistochemical expression of estrogen and progesterone
receptors identifies a subset of NSCLCs and correlates with EGFR
mutation. Clin Cancer Res. 15:5359–5368. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Rouquette I, Lauwers-Cances V, Allera C,
Brouchet L, Milia J, Nicaise Y, Laurent J, Delisle MB, Favre G,
Didier A and Mazières J: Characteristics of lung cancer in women:
Importance of hormonal and growth factors. Lung Cancer. 76:280–285.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang Z, Li Z, Ding X, Shen Z, Liu Z, An T,
Duan J, Zhong J, Wu M, Zhao J, et al: ERbeta localization
influenced outcomes of EGFR-TKI treatment in NSCLC patients with
EGFR mutations. Sci Rep. 5:113922015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Verma MK, Miki Y, Abe K, Nagasaki S,
Niikawa H, Suzuki S, Kondo T and Sasano H: Co-expression of
estrogen receptor beta and aromatase in Japanese lung cancer
patients: Gender-dependent clinical outcome. Life Sci. 91:800–808.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mah V, Marquez D, Alavi M, Maresh EL,
Zhang L, Yoon N, Horvath S, Bagryanova L, Fishbein MC, Chia D, et
al: Expression levels of estrogen receptor beta in conjunction with
aromatase predict survival in non-small cell lung cancer. Lung
Cancer. 74:318–325. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Nose N, Uramoto H, Iwata T, Hanagiri T and
Yasumoto K: Expression of estrogen receptor beta predicts a
clinical response and longer progression-free survival after
treatment with EGFR-TKI for adenocarcinoma of the lung. Lung
Cancer. 71:350–355. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Abe K, Miki Y, Ono K, Mori M, Kakinuma H,
Kou Y, Kudo N, Koguchi M, Niikawa H, Suzuki S, et al: Highly
concordant coexpression of aromatase and estrogen receptor beta in
non-small cell lung cancer. Hum Pathol. 41:190–198. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nose N, Sugio K, Oyama T, Nozoe T, Uramoto
H, Iwata T, Onitsuka T and Yasumoto K: Association between estrogen
receptor-beta expression and epidermal growth factor receptor
mutation in the postoperative prognosis of adenocarcinoma of the
lung. J Clin Oncol. 27:411–417. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Omoto Y, Kobayashi Y, Nishida K, Tsuchiya
E, Eguchi H, Nakagawa K, Ishikawa Y, Yamori T, Iwase H, Fujii Y, et
al: Expression, function, and clinical implications of the estrogen
receptor beta in human lung cancers. Biochem Biophys Res Commun.
285:340–347. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tanaka K, Shimizu K, Kakegawa S, Ohtaki Y,
Nagashima T, Kaira K, Horiguchi J, Oyama T and Takeyoshi I:
Prognostic significance of aromatase and estrogen receptor beta
expression in EGFR wild-type lung adenocarcinoma. Am J Transl Res.
8:81–97. 2016.PubMed/NCBI
|
|
22
|
Schwartz AG, Ray RM, Cote ML, Abrams J,
Sokol RJ, Hendrix SL, Chen C, Chlebowski RT, Hubbell FA, Kooperberg
C, et al: Hormone use, reproductive history, and risk of lung
cancer: The women's health initiative studies. J Thorac Oncol.
10:1004–1013. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Mazieres J, Rouquette I, Lepage B, Milia
J, Brouchet L, Guibert N, Beau-Faller M, Validire P, Hofman P and
Fouret P: Specificities of lung adenocarcinoma in women who have
never smoked. J Thorac Oncol. 8:923–929. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
International Union Against Cancer (UICC),
. TNM Classification of Malignant Tumours. Sobin LH, Gospodarowicz
MK and Wittekind C: 7th. Wiley-Blackwell; Oxford: 2009
|
|
25
|
Travis WD, Brambilla E, Noguchi M,
Nicholson AG, Geisinger KR, Yatabe Y, Beer DG, Powell CA, Riely GJ,
van Schil PE, et al: International association for the study of
lung cancer/american thoracic society/european respiratory society
international multidisciplinary classification of lung
adenocarcinoma. J Thorac Oncol. 6:244–285. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ivanova MM, Mazhawidza W, Dougherty SM and
Klinge CM: Sex differences in estrogen receptor subcellular
location and activity in lung adenocarcinoma cells. Am J Respir
Cell Mol Biol. 42:320–330. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Fasco MJ, Hurteau GJ and Spivack SD:
Gender-dependent expression of alpha and beta estrogen receptors in
human nontumor and tumor lung tissue. Mol Cell Endocrinol.
188:125–140. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kawai H, Ishii A, Washiya K, Konno T, Kon
H, Yamaya C, Ono I, Minamiya Y and Ogawa J: Estrogen receptor alpha
and beta are prognostic factors in non-small cell lung cancer. Clin
Cancer Res. 11:5084–5089. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Schwartz AG, Prysak GM, Murphy V, Lonardo
F, Pass H, Schwartz J and Brooks S: Nuclear estrogen receptor beta
in lung cancer: Expression and survival differences by sex. Clin
Cancer Res. 11:7280–7287. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Márquez-Garbán DC, Chen HW, Fishbein MC,
Goodglick L and Pietras RJ: Estrogen receptor signaling pathways in
human non-small cell lung cancer. Steroids. 72:135–143. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Stabile LP, Dacic S, Land SR, Lenzner DE,
Dhir R, Acquafondata M, Landreneau RJ, Grandis JR and Siegfried JM:
Combined analysis of estrogen receptor beta-1 and progesterone
receptor expression identifies lung cancer patients with poor
outcome. Clin Cancer Res. 17:154–164. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Sun HB, Zheng Y, Ou W, Fang Q, Li P, Ye X,
Zhang BB, Yang H and Wang SY: Association between hormone receptor
expression and epidermal growth factor receptor mutation in
patients operated on for non-small cell lung cancer. Ann Thorac
Surg. 91:1562–1567. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hirschfeld M, Ouyang YQ, Jaeger M, Erbes
T, Orlowska-Volk M, Zur Hausen A and Stickeler E: HNRNP G and
HTRA2-BETA1 regulate estrogen receptor alpha expression with
potential impact on endometrial cancer. BMC Cancer. 15:862015.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Chen M and Manley JL: Mechanisms of
alternative splicing regulation: Insights from molecular and
genomics approaches. Nat Rev Mol Cell Biol. 10:741–754.
2009.PubMed/NCBI
|
